WEISER MICHAEL 4

What Happened
Michael Weiser, a director of Iovance Biotherapeutics, was granted 90,316 deferred restricted stock units (DRSUs) on June 16, 2026. The Form 4 reports the award as 90,316 units at $0.00 (derivative), meaning no cash was paid — this is a compensation grant (transaction code A), not a purchase or sale. Each DRSU is a contingent right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18.
• Transaction type: Award/Grant (A); 90,316 DRSUs; reported price $0.00; classified as a derivative award.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes:
  • F1 — Each DRSU equals a contingent right to one share under the company’s 2018 Equity Incentive Plan (as amended).
  • F2 — Vesting occurs on the earlier of (i) the first anniversary of the grant or (ii) the day before the next annual shareholder meeting, provided continued service. Issuance of shares is deferred until the earlier of (i) three months after the director leaves service (or upon death/disability), (ii) a change in control, or (iii) ten years from the grant date.
• Filing timeliness: Filed two days after the transaction date; the excerpt does not indicate a late filing designation.

Context
DRSUs are a form of deferred compensation commonly used for directors — they do not represent immediately tradable shares until vesting and issuance occur. Because this was a grant rather than a purchase, it signals compensation/retention rather than a personal market bet by the insider. The reported $0.00 is standard for grants on Form 4 and does not reflect the market value the units may ultimately represent.